Investors in Technology

The ALS Investment Fund supports and finances biotech companies that develop drugs and diagnostics for Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease. The ALS Investment Fund was initiated by Dutch ALS patients and is advised by a top-tier European VC firm, Life Sciences Partners. The ALS Investment Fund invests globally, but focuses on Europe and the US. The fund brings depth of disease-specific knowledge and a deep network in the space.

Humanity will always depend on medicines. Continuous innovation in the biotech sector is a given. Bringing better medicines to the market all the time. The Aescap Life Sciences and Aescap Genetics funds invest in highly innovative publicly traded biotech/life sciences companies. These companies are developing tomorrow’s medicines. Investing in Aescap funds offers the possibility to achieve excellent returns over the medium term, without taking large risks. Both funds have a focused portfolio, based on deep fundamental analyses and a strict buy and sell discipline. The Aescap funds act under the Article 8 of the EU Sustainable Finance Disclosure Regulation (SFDR) and operate under a AIFM license.

BFly Ventures (formerly known as WoodWing Ventures), based in Zaandam, the Netherlands, is an early-stage venture capital company. We invest in ambitious, early-stage software companies with creative entrepreneurs, bright ideas, and promising products. Our focus is on nurturing innovation and supporting the growth of businesses that have the potential to disrupt markets and drive technological advancements. By providing both capital and strategic guidance, we help these companies navigate their early stages and accelerate their development. Our commitment is to fostering long-term success and creating value for both the entrepreneurs and our investors.

De Friesland recognizes that innovation is crucial for ensuring the accessibility and affordability of healthcare. That's why we actively invest in numerous organizations and projects dedicated to shaping a sustainable healthcare landscape. By supporting innovative initiatives, we aim to enhance the quality of care while addressing healthcare challenges effectively. Our commitment extends to fostering collaborations and partnerships that drive meaningful advancements in the sector.

RUG Holding is a venture capital firm dedicated to investing in innovative companies within the biotechnology and regulated business sectors. With a strategic focus on fostering advancements in biotech and regulated industries, RUG Holding identifies promising startups and growth-stage enterprises poised for impactful growth and development. The firm provides essential capital, strategic guidance, and operational support to empower portfolio companies in navigating complex regulatory landscapes and accelerating market adoption. By leveraging its expertise and network, RUG Holding aims to drive innovation, facilitate industry leadership, and create sustainable value for its stakeholders. Positioned at the intersection of science, technology, and regulation, RUG Holding plays a crucial role in shaping the future of biotech and regulated markets.

Endeit Capital is a seasoned growth capital firm dedicated to fueling internationalization and fostering innovation within the European tech sector. Since our inception in Amsterdam in 2006, we have diligently supported European tech scale-ups across various industries. With a footprint now spanning three offices across Europe and bolstered by partnerships with 72 visionary entrepreneurs, Endeit Capital boasts a robust portfolio driving technological advancements. At Endeit Capital, we are driven by a profound belief in the transformative power of technology, particularly in AI, machine learning, deep learning, and algorithms. This conviction propels our mission to empower visionary entrepreneurs who are shaping the future.

MIF II, founded in 2015 by Schiphol, KLM, TU Delft, NS, and Port of Amsterdam in collaboration with @NBI Investors, represents a strategic partnership aimed at accelerating entrepreneurial ventures. Combining Venture Capital funding with the specialized expertise and expansive global network of its founding partners, MIF II supports innovative initiatives in Logistics, Transport, and Innovation. Building on the success of Mainport Innovation Fund I, which closed in 2015 after ten impactful investments, MIF II focuses on advancing sustainable infrastructure, connectivity, mobility solutions, intermodal transport, energy innovations, digitization, IoT applications, security and safety enhancements, seamless travel experiences, and big data analytics. By nurturing pioneering technologies and business models, MIF II aims to drive transformative change and shape the future of these critical sectors.

Eyos Capital distinguishes itself as a proactive investment fund specializing in early-stage technology ventures characterized by robust intellectual property. With a hands-on approach, Eyos Capital actively supports promising companies poised for growth and innovation. Their investment strategy centers on identifying and nurturing startups with defensible technological advantages, aiming to position them as leaders in their respective fields. Eyos Capital's portfolio reflects their commitment to fostering entrepreneurial success through strategic guidance and operational support. By leveraging their expertise and network, Eyos Capital plays a pivotal role in accelerating the development and market entry of disruptive technologies, contributing to the evolution of the global tech landscape.

FORWARD.one is a European venture capital firm specializing in investing in hardware innovations across sectors such as Semiconductors, Climate Tech, and High Tech. Founded with a focus on supporting entrepreneurs who are passionate about solving complex challenges through innovative technologies, FORWARD.one seeks to identify and nurture groundbreaking solutions. The firm is dedicated to partnering with early-stage companies, providing not just capital but also strategic guidance and operational support to help them scale and succeed. Committed to making a positive impact, FORWARD.one aims to build a portfolio of companies that drive innovation in their respective fields and contribute to a more sustainable and technologically advanced world.

The Future Food Fund is an early-stage venture capital impact fund focused on investing in food and agriculture companies in North West Europe. Their primary objective is to support and accelerate the transition towards sustainable food systems. By investing in innovative startups in the food and agriculture sectors, the Future Food Fund aims to drive positive environmental and social impact while fostering economic growth. The fund targets companies that are developing groundbreaking solutions to enhance sustainability, reduce waste, and improve efficiency in food production and distribution. By providing essential capital and strategic support, the Future Food Fund empowers entrepreneurs to create scalable and impactful solutions that address the pressing challenges facing the global food system. Through their investments, they are committed to promoting a more sustainable and resilient food ecosystem for future generations.

Boundary Capital Partners LLP is a venture capital firm specializing in early-stage growth companies, primarily within the technology sector. By offering both financial investment and hands-on support, Boundary Capital Partners helps innovative tech startups achieve their growth potential. Their investment approach combines capital with strategic guidance, leveraging their expertise and network to drive business success. Committed to fostering technological advancement, Boundary Capital Partners partners with visionary entrepreneurs to build the next generation of market-leading companies.

Advent Life Sciences is a venture capital firm dedicated to investing in life sciences businesses. Focusing on innovative companies in biotechnology, pharmaceuticals, medical devices, and diagnostics, Advent Life Sciences supports the development of breakthrough technologies and therapies. By providing capital and strategic expertise, the firm helps entrepreneurs navigate the complexities of the life sciences sector, accelerating the path from research to market. Advent Life Sciences is committed to advancing healthcare solutions that improve patient outcomes and address unmet medical needs globally.